{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T03:52:19Z","timestamp":1793159539638,"version":"4.5.0"},"reference-count":123,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.xphs.2021.02.028","type":"journal-article","created":{"date-parts":[[2021,3,9]],"date-time":"2021-03-09T07:35:41Z","timestamp":1615275341000},"page":"2311-2328","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Tolerability of risk: A commentary on the nitrosamine contamination issue"],"prefix":"10.1016","volume":"110","author":[{"given":"David P.","family":"Elder","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David J.","family":"Snodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2021.02.028_bib0001","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.addr.2006.10.007","article-title":"Toxicological overview of impurities in pharmaceutical products","volume":"59","author":"Jacobson-Kram","year":"2007","journal-title":"Adv. Drug Delivery Rev."},{"key":"10.1016\/j.xphs.2021.02.028_bib0002","series-title":"EMA\/CHMP\/CVMP\/QWP\/199250\/2009 corr","article-title":"Guideline on setting specifications for related impurities in antibiotics","year":"2012"},{"key":"10.1016\/j.xphs.2021.02.028_bib0003","unstructured":"ICH Q3D(R1).https:\/\/database.ich.org\/sites\/default\/files\/Q3D-R1EWG_Document_Step4_Guideline_2019_0322.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0004","unstructured":"ICH M7.https:\/\/database.ich.org\/sites\/default\/files\/M7_R1_Guideline.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0005","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.yrtph.2019.01.007","article-title":"Short commentary on NDMA (N-nitrosodimethylamine) contamination of valsartan products","volume":"103","author":"Snodin","year":"2019","journal-title":"Reg Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2021.02.028_bib0006","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1021\/op500346q","article-title":"Is avoidance of genotoxic intermediates\/impurities tenable for complex, multistep syntheses?","volume":"19","author":"Elder","year":"2015","journal-title":"Org Proc Res Dev"},{"key":"10.1016\/j.xphs.2021.02.028_bib0007","series-title":"Committee for Human Medicinal Products","article-title":"ICH guideline Q3C (R6) on impurities: guideline for residual solvents, Step 5","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0008","series-title":"Pharmaceutical Stress Testing. Predicting drug Degradation","first-page":"49","article-title":"Stress testing the chemistry of drug degradation","author":"Baertschi","year":"2011"},{"key":"10.1016\/j.xphs.2021.02.028_bib0009","series-title":"The Tolerability of Risk: A New Framework for Risk Management","first-page":"1","author":"Bouder","year":"2009"},{"key":"10.1016\/j.xphs.2021.02.028_bib0010","unstructured":"ICH Q3A(R2).https:\/\/database.ich.org\/sites\/default\/files\/Q3A%28R2%29%20Guideline.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0011","unstructured":"ICH Q3B(R2). Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q3B%28R2%29%20Guideline.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0012","unstructured":"ICH Q3C(R6). Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q3C-R6_Guideline_ErrorCorrection_2019_0410_0.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0013","unstructured":"ICH Q6A. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q6A%20Guideline.pdf. Accessed March 17, 2021.."},{"key":"10.1016\/j.xphs.2021.02.028_bib0014","unstructured":"ICHQ6B. Available at: https:\/\/database.ich.org\/sites\/default\/files\/Q6B%20Guideline.pdf. Accessed on March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0015","unstructured":"ICH M3(R2). Available at: https:\/\/database.ich.org\/sites\/default\/files\/M3_R2__Guideline.pdf. Accessed on March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0016","unstructured":"ICH S9. Available at: https:\/\/database.ich.org\/sites\/default\/files\/S9_Guideline.pdf. Accessed March 17, 2021."},{"issue":"4","key":"10.1016\/j.xphs.2021.02.028_bib0017","first-page":"10","article-title":"Exposure based limits for controlling impurities","volume":"20","author":"Elder","year":"2017","journal-title":"Am Pharm Rev"},{"issue":"2","key":"10.1016\/j.xphs.2021.02.028_bib0018","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.yrtph.2012.03.016","article-title":"Guidelines and pharmacopoeial standards for pharmaceutical impurities: overview and critical assessment","volume":"63","author":"Snodin","year":"2012","journal-title":"Reg Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2021.02.028_bib0019","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1021\/op300268u","article-title":"Risk assessment of genotoxic impurities in new chemical entities: strategies to demonstrate control","volume":"17","author":"Teasdale","year":"2013","journal-title":"Org Proc Res Dev"},{"key":"10.1016\/j.xphs.2021.02.028_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.yrtph.2020.104749","article-title":"Are all nitrosamines concerning? A review of mutagenicity and carcinogenicity data","volume":"116","author":"Thresher","year":"2020","journal-title":"Reg Toxicol Pharmacol"},{"issue":"50","key":"10.1016\/j.xphs.2021.02.028_bib0021","doi-asserted-by":"crossref","first-page":"9995","DOI":"10.1021\/bi301092c","article-title":"Oxidation of methyl and ethyl nitrosamines by cytochromes P450 2E1 and 2B1","volume":"51","author":"Chowdhury","year":"2012","journal-title":"Biochemical"},{"key":"10.1016\/j.xphs.2021.02.028_bib0022","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.mrgentox.2006.10.003","article-title":"Strategy for genotoxicity testing: hazard identification and risk assessment in relation to in vitro testing","volume":"627","author":"Thybaud","year":"2007","journal-title":"Mutat Res"},{"key":"10.1016\/j.xphs.2021.02.028_bib0023","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/mutage\/geq089","article-title":"Potential thresholds for genotoxic effects by micronucleus scoring","volume":"26","author":"Elhajouji","year":"2011","journal-title":"Mutagenesis"},{"key":"10.1016\/j.xphs.2021.02.028_bib0024","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/mutage\/geg003","article-title":"Investigations into the concept of a threshold for topoisomerase inhibitor-induced clastogenicity","volume":"18","author":"Lynch","year":"2003","journal-title":"Mutagenesis"},{"key":"10.1016\/j.xphs.2021.02.028_bib0025","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/toxsci\/kfq341","article-title":"N-methylpurine DNA glycosylase plays a pivotal role in the threshold response of ethyl methanesulfonate-induced chromosome damage","volume":"119","author":"Zair","year":"2011","journal-title":"Tox Sci"},{"key":"10.1016\/j.xphs.2021.02.028_bib0026","first-page":"15","article-title":"The assessment of mutagenicity","volume":"21","year":"1993","journal-title":"Health Protection Branch Mutagenicity Guidelines. Health Protection Branch Genotoxicity Committee"},{"key":"10.1016\/j.xphs.2021.02.028_bib0027","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1093\/carcin\/19.7.1239","article-title":"Repair of DNA lesions induced by polycyclic aromatic hydrocarbons in human cell-free extracts: involvement of two excision repair mechanisms in vitro","volume":"19","author":"Braithwaite","year":"1998","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.xphs.2021.02.028_bib0028","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.mrgentox.2014.10.008","article-title":"WGT report on quantitative approaches to genotoxicity risk assessment II. Use of point-of-departure (PoD) metrics in defining acceptable exposure limits and assessing human risk","volume":"783","author":"MacGregor JT Fr\u00f6tschl","year":"2015","journal-title":"Mut Res"},{"issue":"3","key":"10.1016\/j.xphs.2021.02.028_bib0029","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1080\/02763860802198895","article-title":"CPDB: carcinogenic potency database","volume":"27","author":"Fitzpatrick","year":"2008","journal-title":"Med Ref Serv Q. Fall"},{"key":"10.1016\/j.xphs.2021.02.028_bib0030","unstructured":"EMA. 2020 a. Procedure under Article 5(3) of Regulation EC (No) 726\/2004 Nitrosamine impurities in human medicinal products. EMEA\/H\/A-5(3)\/1490. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/nitrosamines-emea-h-a53-1490-assessment-report_en.pdf. Accessed March 17, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0031","series-title":"Lessons Learnt from Presence of N-nitrosamine Impurities in Sartan Medicines","year":"2020"},{"issue":"23 Pt 2","key":"10.1016\/j.xphs.2021.02.028_bib0032","first-page":"6452","article-title":"Dose and time relationships for tumor induction in the liver and esophagus of 4080 inbred rats by chronic ingestion of N-nitrosodiethylamine or N- nitrosodimethylamine","volume":"51","author":"Peto","year":"1991","journal-title":"Cancer Res"},{"issue":"23 Pt 2","key":"10.1016\/j.xphs.2021.02.028_bib0033","first-page":"6415","article-title":"Effects on 4080 rats of chronic ingestion of N-nitrosodiethylamine or N-nitrosodimethylamine: a detailed dose-response study","volume":"51","author":"Peto","year":"1991","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.xphs.2021.02.028_bib0034","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/toxsci\/kfq093","article-title":"Risk assessment of N-nitrosodimethylamine formed endogenously after fish-with-vegetable meals","volume":"116","author":"Zeilmaker","year":"2010","journal-title":"Toxicol.Sci"},{"key":"10.1016\/j.xphs.2021.02.028_bib0035","unstructured":"EMA, 2019 a. Assessment Report. EMA\/217823\/2019, February 14, 2019."},{"key":"10.1016\/j.xphs.2021.02.028_bib0036","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1146\/annurev.publhealth.18.1.313","article-title":"Food safety regulation: reforming the delaney clause","volume":"18","author":"Merrill","year":"1997","journal-title":"Annu Rev Public Health"},{"issue":"6","key":"10.1016\/j.xphs.2021.02.028_bib0037","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1038\/nbt.3606","article-title":"The US regulatory and pharmacopoeia response to the global heparin contamination crisis","volume":"34","author":"Szajek","year":"2016","journal-title":"Nat Biotechnol"},{"issue":"5","key":"10.1016\/j.xphs.2021.02.028_bib0038","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1208\/s12249-019-1376-1","article-title":"Lessons learnt from the recall of Valsartan and otherangiotensin II receptor blockade drugs containing NDMA and NDEA impurities","volume":"20","author":"Charoo","year":"2019","journal-title":"AAPS PharmSciTech"},{"issue":"2","key":"10.1016\/j.xphs.2021.02.028_bib0039","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.yrtph.2007.06.008","article-title":"An impact analysis of the application of the threshold of toxicological concern concept to pharmaceuticals","volume":"49","author":"Delaney","year":"2007","journal-title":"Regul Toxicol Pharmacol"},{"key":"10.1016\/j.xphs.2021.02.028_bib0040","unstructured":"EMA, 2018 a. Update on review of recalled valsartan medicines: preliminary assessment of possible risk to patients. EMA\/526031\/2018, August 02, 2018."},{"key":"10.1016\/j.xphs.2021.02.028_bib0041","unstructured":"Christensen J. Available at: https:\/\/www.kyma.com\/health\/common-heart-drug-recalled-in-22-countries-for-possible-cancer-link\/764127741. 2018. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0042","unstructured":"Perscheid M. How Did N-Nitroso-Dimethylamine (NDMA) Get into Valsartan? Available at: https:\/\/www.linkedin.com\/pulse\/how-did-n-nitroso-dimethylamine-ndma-mm048709-get-moritz-perscheid. Accessed on July 20, 2020."},{"issue":"1","key":"10.1016\/j.xphs.2021.02.028_bib0043","first-page":"38","article-title":"Sartan recalls beg the question: is compendial impurity testing enough?","volume":"30","author":"Shanley","year":"2018","journal-title":"Pharm Tech Eur"},{"key":"10.1016\/j.xphs.2021.02.028_bib0044","unstructured":"FDA, 2018 a. Update- FDA updates recalled valsartan- containing product information and. presents NDMA levels in some foods, 20 August 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb recalls-valsartan-losartan#5f16904a2e9db. Accessed on July 04, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0045","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.fct.2015.03.008","article-title":"Dietary exposure to volatile and non-volatile N-nitrosamines from processed meat products in Denmark","volume":"80","author":"Herrmann","year":"2015","journal-title":"Food Chem Toxicol"},{"key":"10.1016\/j.xphs.2021.02.028_bib0046","unstructured":"FDA, 2018 b. Update- Analysis of N-nitrosodimethylamine (NDMA) levels in recalled valsartan in the U.S. 27 July 2018. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5f16904a2edb2. Accessed on July 04, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0047","unstructured":"Gottlieb S., Woodcock J. FDA Statement on the FDA's Ongoing Investigation Into Valsartan and ARB Class Impurities and the Agency's Steps to Address the Root Causes of the Safety Issues. 25 January 2019a. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-statement-fdas-ongoing-investigation-valsartan-and-arb-class-impurities-and-agencys-steps. Accessed on July 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0048","series-title":"Statement on the Agency's Ongoing Efforts to Resolve Safety Issue with ARB Medications","author":"Woodcock","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0049","unstructured":"EMA, 2019 b. EMA advises companies on steps to take to avoid nitrosamines in human medicines. 26\/09\/2019. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-companies-steps-take-avoid-nitrosamines-human-medicines. Accessed on July 04, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0050","series-title":"FDA Works to Mitigate Shortages of Rifampin and Rifapentine After Manufacturers Find Nitrosamine Impurities","year":"2020"},{"issue":"5","key":"10.1016\/j.xphs.2021.02.028_bib0051","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1161\/CIRCULATIONAHA.119.044494","article-title":"Population impact of generic valsartan recall","volume":"141","author":"Jackevicius","year":"2020","journal-title":"Circulation"},{"key":"10.1016\/j.xphs.2021.02.028_bib0052","doi-asserted-by":"crossref","first-page":"k3851","DOI":"10.1136\/bmj.k3851","article-title":"Use of N-nitrosodimethylamine (NDMA) contaminated valsartan products and risk of cancer: Danish nationwide cohort study","volume":"362","author":"Potteg\u00e5rd","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.xphs.2021.02.028_bib0053","doi-asserted-by":"crossref","first-page":"k3855","DOI":"10.1136\/bmj.k3855","article-title":"Regulatory response to contaminated valsartan","volume":"362","author":"Banzi","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.xphs.2021.02.028_bib0054","series-title":"EMA\/459276\/2018","article-title":"EMA reviewing medicines containing valsartan from Zhejianjg Huahai following the detection of an impurity","year":"2018"},{"key":"10.1016\/j.xphs.2021.02.028_bib0055","series-title":"FDA Announces Voluntary Recall of Several Medicines Containing Valsartan Following Detection of an Impurity","year":"2018"},{"key":"10.1016\/j.xphs.2021.02.028_bib0056","series-title":"Issues Voluntary Nationwide Recall of Valsartan Tablets, USP, 40 mg, 80 mg, 160 Mg and 320 Mg Due to The Detection of Trace Amounts of N-Nitrosodimethylamine (NDMA) Impurity, Found in an Active Pharmaceutical Ingredient (API)","year":"2018"},{"issue":"3","key":"10.1016\/j.xphs.2021.02.028_bib0057","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/cpt.1617","article-title":"Are the European medicines agency, us food and drug administration, and other international regulators talking to each Other?","volume":"107","author":"Teixeira","year":"2020","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.xphs.2021.02.028_bib0058","unstructured":"FDA, 2018 d Update \u2013 FDA releases method for detection of both NDMA and NDEA. 11 October 2018. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5f16904a2e431. Accessed on July 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0059","unstructured":"FDA, 2018 e. Update- FDA alerts patients and health care professionals to ScieGen's Irbesartan recall due to NDEA. 30 October 2018. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5f16904a2e1d7. Accessed on July 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0060","unstructured":"FDA, 2018 f. Update \u2013 FDA alerts patients and health care professionals to Sandoz's Losartan Potassium and Hydrochlorothiazide recall of one lot due to NDEA. 09 November 2018. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5f16904a2e14a. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0061","unstructured":"EMA, 2018 c. Valsartan: review of Impurities Extended to Other Sartan Medicines. 21\/09\/18. Available at: https:\/\/www.ema.europa.eu\/news\/valsartan-review-impurities-extendedother-sartan-medicines. Accessed date: July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0062","unstructured":"EMA, 2019 d Update on nitrosamine impurities: EMA continues to work to prevent impurities in medicines. 26 April 2019, EMA\/241020\/2019."},{"key":"10.1016\/j.xphs.2021.02.028_bib0063","unstructured":"EMA, 2019 f. EMA advises companies on steps to take to avoid nitrosamines in human medicines, 26 Sep 2019 and subsequent Covid-19 extension, 04 May 2020. Available at: https:\/\/www.ema.europa.eu\/en\/news\/ema-advises-companies-steps-take-avoid-nitrosamines-human-medicines. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0064","unstructured":"Health Canada, 2019. Questions and Answers. Request to evaluate the risk of the presence N-nitrosamine impurities in human pharmaceutical products. 02 October 2019 and subsequent Covid-19 extension, 26 March 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0065","unstructured":"Swiss Medic, 2019. Potential nitrosamine contamination: request to perform a risk evaluation. 19 November 2019 and subsequent Covid-19 extension, 03 April 2020. Available at:https:\/\/www.swissmedic.ch\/swissmedic\/en\/home\/news\/mitteilungen\/aufforderung-zlinhaberinnen-ham.html. Accessed on July 11, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0066","unstructured":"WHO, 2019. Essential medicines and health products. I nformation Note Nitrosamine Impurities. Update on nitrosamine impurities. Available at: https:\/\/www.who.int\/medicines\/publications\/drugalerts\/InformationNote_Nitrosamine-impurities\/en\/. Accessed on July 17, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0067","series-title":"EMA Urges Pioglitazone Manufacturers to Check for Nitrosamine Impurities","author":"Brennan","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0068","unstructured":"FDA, 2019 a. FDA provides update on its ongoing investigation into ARB drug products; reports on finding of a new nitrosamine impurity in certain lots of losartan and product recall, 01 March 2019. Available at: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-provides-update-its-ongoing-investigation-arb-drug-products-reports-finding-new-nitrosamine. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0069","series-title":"FDA Statement on the Agency's List of Known Nitrosamine-Free Valsartan and ARB Class medicines, as Part of Agency's Ongoing Efforts to Resolve Ongoing Safety Issue, 04 April 2019","author":"Gottlieb","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0070","unstructured":"Valisure Citizen Petition on Ranitidine, September 9, 2019: Available at: https:\/\/www.valisure.com\/wp-content\/uploads\/Valisure-Ranitidine-FDA-Citizen-Petition-v4.12.pdf. Accessed on July 04, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0071","series-title":"Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of NDMA in Ranitidine Drug Substance and Drug Product","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0072","unstructured":"EMA, 2020 c. Suspension of ranitidine medicines in the EU. Update of 26 June 2020. EMA\/231394\/2020. Rev.1. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/ranitidine-article-31-referral-suspension-ranitidine-medicines-eu_en.pdf. Accessed date: July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0073","series-title":"Statement from Janet Woodcock, M.D., director of FDA's Center for Drug Evaluation and Research, on Impurities Found in Diabetes Drugs Outside the U.S. December 05, 2019","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0074","unstructured":"FDA, 2020 b. Statement. FDA posts laboratory results for NDMA levels in metformin, 03 February 2020. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-metformin#5f153851dc977. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0075","unstructured":"Valisure, 2.0.2.0. Re: valisure Citizen Petition on Metformin, 02 March 2020. Available at: https:\/\/www.valisure.com\/wp-content\/uploads\/Valisure-FDA-Citizen-Petition-on-Metformin-v3.9.pdf. Accessed on July 20, 2020."},{"issue":"89","key":"10.1016\/j.xphs.2021.02.028_bib0076","first-page":"1","article-title":"A cautionary tale: quantitative LC-HRMS analytical procedures for the analysis of M-nitrosodimethylamine in metformin","volume":"22","author":"Yang","year":"2020","journal-title":"AAPS J"},{"key":"10.1016\/j.xphs.2021.02.028_bib0077","series-title":"FDA Alerts Patients and Health Care Professionals to Nitrosamine Impurity Findings in Certain Metformin Extended-Release Products","year":"2020"},{"key":"10.1016\/j.xphs.2021.02.028_bib0078","unstructured":"FDA, 2020 d FDA Updates and Press Announcements on NDMA in Zantac (ranitidine). FDA is alerting patients and health care professionals to Amneal Pharmaceutical's voluntary recall of nizatidine. 16 April 2020. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-ndma-zantac-ranitidine. Accessed on July 04, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0079","unstructured":"Health Canada, Risk of NDMA formation in doxylamine succinate products, 19 July 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0080","unstructured":"Nitrosamine impurities. Guidance for Marketing Authorisation Holds. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities#rifampicin-medicines-section. Accessed on December 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0081","unstructured":"Nitrosamine impurities. Rifampicin medicines. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities#rifampicin-medicines-section. Accessed December 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0082","series-title":"Regulatory Hot Topics V. Joint Pharmaceutical Symposium","article-title":"N-Nitrosamine Update","author":"Boon","year":"2020"},{"key":"10.1016\/j.xphs.2021.02.028_bib0083","unstructured":"FDA, 2020 e. FDA works to mitigate shortages of rifampin and rifapentine after manufacturers find nitrosamine impurities. FDA not objecting to rifapentine with CPNP at or below 20 ppm remaining on the market. Update 10\/29\/2020. Available at:https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine. Accessed on October 30, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0084","unstructured":"Nitrosamine Impurities. Metformin containing medicines. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities#metformin-containing-medicines-section. Accessed December 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0085","unstructured":"Nitrosamine Impurities. Rifampicin containing medicines. Available at: https:\/\/www.ema.europa.eu\/en\/human-regulatory\/post-authorisation\/referral-procedures\/nitrosamine-impurities#rifampicin-medicines-section. Accessed on December 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0086","series-title":"After Valsartan Recalls, Regulators Grapple with Nitrosamine Contamination in APIs","author":"Shanley","year":"2018"},{"issue":"11","key":"10.1016\/j.xphs.2021.02.028_bib0087","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1021\/op3001788","article-title":"Carry over of impurities: a detailed exemplification for glycopyrrolate (NVA237)","volume":"16","author":"Allmendinger","year":"2012","journal-title":"Org Proc Res Dev"},{"issue":"8","key":"10.1016\/j.xphs.2021.02.028_bib0088","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1021\/acs.oprd.0c00264","article-title":"Controlling a cohort: use of mirabilis-based purge calculations to understand nitrosamine-related risk and control strategy options","volume":"24","author":"Burns","year":"2020","journal-title":"Org Proc Res Dev"},{"key":"10.1016\/j.xphs.2021.02.028_bib0089","unstructured":"FDA, 2019 c. Laboratory analysis of ranitidine and nizatidine products. 01 November 2019. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/laboratory-tests-ranitidine. Accessed on July 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0090","unstructured":"FDA, 2019 d FDA updates table of interim limits for nitrosamine impurities in ARBs. Update 2\/28\/2019. Available at: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-updates-and-press-announcements-angiotensin-ii-receptor-blocker-arb-recalls-valsartan-losartan#5f16904a2cdf. Accessed on July 18, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0091","series-title":"Update \u2013 FDA warns Mylan for cGMP violations, 13 November 2019","year":"2019"},{"key":"10.1016\/j.xphs.2021.02.028_bib0092","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jes.2017.05.028","article-title":"Characterization of N-nitrosodimethylamine formation from the ozonation of ranitidine","volume":"58","author":"Lv","year":"2017","journal-title":"J Environ Sci (China)"},{"key":"10.1016\/j.xphs.2021.02.028_bib0093","unstructured":"WHO, 2008. N-Nitrosodimethylamine in Drinking-water. Background document foe development of WHO Guidelines for Drinking-water Quality. Available at: https:\/\/www.who.int\/water_sanitation_health\/dwq\/chemicals\/ndma_2add_feb2008.pdf. Accessed on December 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0094","unstructured":"WHO Guidelines for Drinking-water Quality. Available at: https:\/\/www.who.int\/water_sanitation_health\/dwq\/chemicals\/ndma_2add_feb2008.pdf?ua=1. Accessed on October 30, 2020."},{"issue":"9","key":"10.1016\/j.xphs.2021.02.028_bib0095","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1021\/acs.oprd.0c00224","article-title":"Potential for the formation of N-Nitrosamines during the manufacture of active pharmaceutical ingredients: an assessment of the risk posed by trace nitrite in water","volume":"24","author":"Ashworth","year":"2020","journal-title":"Org Proc Res Dev"},{"issue":"4","key":"10.1016\/j.xphs.2021.02.028_bib0096","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1208\/s12249-011-9677-z","article-title":"Reactive impurities in excipients: profiling, identification and mitigation of drug\u2013excipient incompatibility","volume":"12","author":"Wu","year":"2011","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.xphs.2021.02.028_bib0097","unstructured":"ANSM (French National Agency for Medicines and Health Product Safety), 2018. Determination of NDMA in valsartan active substances and finished products by HPLC\/UV, Method reference: 18A0399-02. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/omcl-method-determination-ndma-valsartan-ansm-september2018.pdf. Accessed on July 21, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0098","unstructured":"PALG (Public Analyst's Laboratory Galloway, Ireland), 2018. Determination of NDMA (HS-GC-MS), Method 3\/30 Issue No. 1. Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/omcl-ndma-method-palg-ie-september2018.pdf. Accessed on July 21, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0099","series-title":"Test Method for the Determination of NDMA By LC\/MS\/MS in Valsartan finished Products","year":"2018"},{"key":"10.1016\/j.xphs.2021.02.028_bib0100","unstructured":"LDL (Bayerisches Landesamt f\u00fcr Gesundheit und Lebensmittelsicherheit), 2018. LC-MS\/MS Method \u00b4190321_NMBA_APCI_POS_waste\u00b4 (Shimadzu HPLC\u202f+\u202fSciex QTrap 5500): Available at: https:\/\/www.edqm.eu\/sites\/default\/files\/de_lgl_losartan_method_parameters_nmba_lcms.pdf. Accessed on July 21, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0101","unstructured":"OMCL, 2020. Ad-hoc projects of the OMCL Network.https:\/\/www.edqm.eu\/en\/ad-hoc-projects-omcl-network. Accessed on October 30, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0102","series-title":"Last Chance to Comment: Analysis of N-Nitrosamine Impurities","year":"2020"},{"key":"10.1016\/j.xphs.2021.02.028_bib0103","series-title":"GC\/MS Headspace Method for Detection of NDMA in Valsartan Drug Substance","year":"2018"},{"key":"10.1016\/j.xphs.2021.02.028_bib0104","unstructured":"FDA, 2018 h. Combined direct injection N-nitrosodimethylamine (NDMA) and N-nitrosodiethylamine (NDEA) Impurity Assay by GC\/MS. Available at: https:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM623578.pdf. Accessed on July 11, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0105","unstructured":"FDA, 2019 f. Combined Direct Injection N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), and N-Nitrosodibutylamine (NDBA) Impurity Assay by GC-MS\/MS. 04\/19\/2019. Available at: https:\/\/www.fda.gov\/media\/123409\/download. Accessed on July 21, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0106","unstructured":"FDA, 2019 g. Combined Headspace N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), and N-Nitrosodiisopropylamine (NDIPA) Impurity Assay by GC-MS\/MS. 29\/04\/2020. Available at: https:\/\/www.fda.gov\/media\/124025\/download. Accessed on October 16, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0107","unstructured":"FDA, 2019 h. Liquid Chromatography-High Resolution Mass Spectrometry (LC-HRMS) Method for the Determination of Six Nitrosamine Impurities in ARB Drugs. 05\/21\/19. Available at: https:\/\/www.fda.gov\/media\/125478\/download. Accessed on October 16, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0108","unstructured":"FDA, 2019 i. Development and validation of a RapidFire-MS\/MS method for screening of nitrosamine carcinogen impurities N-Nitrosodimethylamine (NDMA), N-Nitrosodiethylamine (NDEA), N-Nitrosoethylisopropylamine (NEIPA), N-Nitrosodiisopropylamine (NDIPA), N-Nitrosodibutylamine (NDBA) and N-Nitroso-N-methyl-4-aminobutyric acid (NMBA) in ARB drugs. 07\/24\/2019. Available at: https:\/\/www.fda.gov\/media\/125477\/download. Assessed on October 16, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0109","unstructured":"PF, 2020. General Chapter Prospectus: <1469>Nitrosamine Impurities. 24 April 2020. Available at: https:\/\/www.uspnf.com\/notices\/nitrosamine-impurities-gc-prospectus-20200424. Accessed on October 16, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0110","unstructured":"SwissMedic, 2020. Pr\u00fcfvorschrift 31_PV_171 Nitrosamine mittels GC-MS\/MS. Pr\u00fcfvorschrift 31_PV_171 Nitrosamine mittels GC-MS\/MS."},{"key":"10.1016\/j.xphs.2021.02.028_bib0111","unstructured":"Health Canada, 2020. Determination of N-Nitrosodimethylamine (NDMA) and N-Nitrosodiethylamine (NDEA) by GC-MS-MS (Direct Injection) in Sartan Finished Products and Drug Substances. Available at: https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/compliance-enforcement\/information-health-product\/drugs\/angiotensin-receptor-blocker.html#a4. Accessed on October 17, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0112","unstructured":"Taiwanese FDA, 2020 a. Determination of N-Nitrosodimethylamine and N-Nitrosodiethylamine in Medicines. Issued Aug 10, 2018, Revised, Nov 14, 2018, Revised, Sep 27, 2019, Revised, Dec 12, 2019. Available at: https:\/\/www.fda.gov.tw\/ENG\/siteList.aspx?sid=10360. 9 Accessed on October 17, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0113","unstructured":"Taiwanese FDA, 2020 b. Determination of N-Nitroso-N-Methyl-4-Aminobutyric Acid in Sartan Drug Substances and Drug Products. Issued Apr 10, 2019, Revised, May 22, 2019, Revised, Jul 28, 2020. Available at: https:\/\/www.fda.gov.tw\/ENG\/siteList.aspx?sid=10360. Accessed on October 17, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0114","series-title":"Method of Test for Nitrosamines in Medicines \u2013 Multiple Analysis. Issued","year":"2020"},{"key":"10.1016\/j.xphs.2021.02.028_bib0115","unstructured":"Biba E., 2020. USP general chapter <1469>Nitrosamine Impurities. Available at: http:\/\/kpbma.or.kr\/api_board\/download\/seminar\/454 Accessed on October 16, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0116","series-title":"Good Manufacturing Practice for Active Pharmaceutical Ingredients","year":"2000"},{"key":"10.1016\/j.xphs.2021.02.028_bib0117","unstructured":"ICH Q9, 2005. Quality risk management. Current Step 4 version dated 9 November 2005."},{"key":"10.1016\/j.xphs.2021.02.028_bib0118","unstructured":"EC, 2012. EudraLex. The Rules Governing Medicinal Products in the European Union, Volume 4. EU Guidelines for Good Manufacturing Practice for Medicinal Products for Human and Veterinary Use. Chapter 7, Outsourced Activities. SANCO\/AM\/sl\/ddg1.d.6(2012)860362. Available at: https:\/\/ec.europa.eu\/health\/sites\/health\/files\/files\/eudralex\/vol-4\/vol4-chap7_2012-06_en.pdf. Accessed on October 20, 2020."},{"key":"10.1016\/j.xphs.2021.02.028_bib0119","series-title":"Hydrazoic Acid","year":"2020"},{"key":"10.1016\/j.xphs.2021.02.028_bib0120","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1080\/00304949409458050","article-title":"Recent developments in tetrazole chemistry. A review","volume":"26","author":"Wittenberger","year":"1994","journal-title":"Org Prep Proced Int"},{"key":"10.1016\/j.xphs.2021.02.028_bib0121","doi-asserted-by":"crossref","unstructured":"N Hart RJ, Walters CL, et al. Susceptibilities of drugs to nitrosation under standardized chemical conditions. Food Chem Toxicol. 1984;22. 1984269\u201327.","DOI":"10.1016\/0278-6915(84)90005-X"},{"key":"10.1016\/j.xphs.2021.02.028_bib0122","unstructured":"FDA, 2021, Control of Nitrosamine Impurities in Human Drugs \u2013 Guidance for Industry R1, FDA CDER CGMP. Available at: https:\/\/www.fda.gov\/media\/141720\/download. Accessed March 31, 2021."},{"key":"10.1016\/j.xphs.2021.02.028_bib0123","unstructured":"EMA, 2021, European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726\/2004 for nitrosamine impurities in human medicines. Available at: https:\/\/www.ema.europa.eu\/en\/documents\/referral\/european-medicines-regulatory-network-approach-implementation-chmp-opinion-pursuant-article-53\/2004-nitrosamine-impurities-human-medicines_en.pdf. Accessed March 31, 2021."}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921001362?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354921001362?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:33:19Z","timestamp":1758360799000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354921001362"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":123,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S0022354921001362"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2021.02.028","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of risk: A commentary on the nitrosamine contamination issue","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2021.02.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}